HMR 59

Drug Profile

HMR 59

Alternative Names: AAVCAGsCD59; HMR59

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tufts University
  • Developer Hemera Biosciences; Tufts University
  • Class Eye disorder therapies; Gene therapies; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dry age-related macular degeneration
  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 29 Mar 2017 Phase-I clinical trials in Dry age-related macular degeneration (In the elderly) in USA (Parenteral) (NCT03144999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top